{
  "num_tested_probands": [
    [
      1
    ],
    [
      4
    ],
    [
      1
    ],
    [
      32
    ]
  ],
  "num_positive_het_probands": [
    [
      0
    ],
    [
      0
    ],
    [
      0
    ],
    [
      0
    ]
  ],
  "positive_phenotypes": [
    [
      "SS"
    ],
    [
      "homozygous for silent mutations",
      "compound heterozygous for two silent mutations"
    ],
    [
      "SS",
      "homozygous for the atypical mutation AA"
    ],
    [
      "Silent phenotype",
      "Hypocholinesterasemia"
    ]
  ],
  "num_compound_or_double_hets": [
    [
      1
    ],
    [
      1
    ],
    [
      1
    ],
    [
      1
    ]
  ],
  "explanation": {
    "num_tested_probands": [
      [
        "The patient was the only proband tested in this case report."
      ],
      [
        "The patient and his family members had blood samples drawn to determine BChE activity, phenotype, and genotype."
      ],
      [
        "The patient was the only proband tested in this report."
      ],
      [
        "The number of probands tested is 32, as reported in the references."
      ]
    ],
    "num_positive_het_probands": [
      [
        "No heterozygous probands were identified in this study."
      ],
      [
        "None of the probands were heterozygous for a pathogenic variant."
      ],
      [
        "No heterozygous probands were reported to have a pathogenic variant."
      ],
      [
        "No proband with a positive heterozygous mutation was found."
      ]
    ],
    "positive_phenotypes": [
      [
        "The patient had a phenotype of SS, indicating compound heterozygosity for silent mutations."
      ],
      [
        "The patient's BChE activity was zero, indicating that he was homozygous for silent mutations. A pedigree and the biochemical data for the patient and his family are shown in Figure 4."
      ],
      [
        "The patient had SS phenotype and was homozygous for the atypical mutation AA. This is consistent with the expected clinical presentation of patients with this genotype."
      ],
      [
        "The silent phenotype and hypocholinesterasemia were identified in some cases."
      ]
    ],
    "num_compound_or_double_hets": [
      [
        "One compound/double heterozygote was reported in the case report."
      ],
      [
        "The patient is compound heterozygous for two silent mutations."
      ],
      [
        "One compound heterozygous proband was reported to have a silent mutation."
      ],
      [
        "One compound or double heterozygote was reported."
      ]
    ]
  },
  "quote_snippets": [
    [
      "The patient was compound heterozygous for silent mutations in the butyrylcholinesterase gene.",
      "Patients who are homozygous for the atypical mutation, compound heterozygous for atypical and a silent mutation, or homozygous for silent mutations respond to mivacurium with extensively prolonged durations of action.",
      "Although important, exact phenotyping of these patients is difficult."
    ],
    [
      "mutations in BCHE gene were detected by direct comparison with the sequence of the normal genotype.",
      "the patient and one brother are homozygous for silent mutations, whereas the father, the mother, and the other brother are heterozygous for a silent mutation.",
      "the patient is compound heterozygous for two silent mutations.",
      "correct genotyping of the patient and his family necessitated a molecular genetic approach including complete nucleotide sequencing of the coding region of BCHE."
    ],
    [
      "mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.",
      "com-",
      "pound",
      "in \ufb01ve patients with AA phenotype.2 Therefore, it is not surprising that nearly five times this dose (mivacurium, 140 mg/kg) administered to our patient caused a very prolonged block, with reappearance of T1 after 274 min.",
      "This is in agreement with data for patients homozygous for the atypical mutation (\u00d8stergaard et al.: ANESTHESIOLOGY 1997; 87(suppl 3A):A854 [abstract]).",
      "The active isomers were present in plasma up to 419 min after the administration of mivacurium.",
      "In healthy patients, the cis-trans and the trans-trans isomers were measurable for 20 and 30 min, respectively.21 In patients with normal phenotypes but decreased BChE activity, the corresponding values were 30 and 40 min, respec-",
      "tively.21 Furthermore, in patients with bambuterol-in-duced low BChE, the isomers were detectable for 60 min.",
      "The terminal elimination half-lives of mivacurium in patients with silent mutations are not well established.",
      "In conclusion, our results indicate that patients who are compound heterozygous for silent mutations in the BCHE respond to mivacurium by extensively prolonged duration of its action,"
    ],
    [
      "mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.",
      "a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT3GGAG).",
      "mutations of butyrylcholine esterase identi\ufb01ed from phenotypic abnormalities in Japan.",
      "a Japanese patient with butyrylcholinesterase deficiency.",
      "mutations of human butyrylcholinesterase gene in a family with hypocholines-terasemia.",
      "nonsense mutation in exon 2 of the butyrylcholinesterase gene: a case of familial cholinesterasemia.",
      "inactivation of the cholinesterase gene by Alu insertion: possible mechanism for human gene transposition.",
      "one common mutation and two novel silent genes."
    ]
  ]
}